Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers
source: pixabay.com

Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers

While novel treatments have been rapidly emerging onto the drug scene, new treatment options for pancreatic cancer have fallen behind. But now, according to OncLive’s interview with Dr. P.A. Philip,…

Continue Reading Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers
Phase 1b Data Shows Magrolimab Clinical Response for AML
source: pixabay.com

Phase 1b Data Shows Magrolimab Clinical Response for AML

In early December 2020, biopharmaceutical company Gilead Sciences, Inc. ("Gilead") shared updated results from a Phase 1b clinical trial evaluating magrolimab for patients with treatment-naïve acute myeloid leukemia (AML). Generally,…

Continue Reading Phase 1b Data Shows Magrolimab Clinical Response for AML
A New Treatment for BPDCN is on Track for EU Approval
source: pixabay.com

A New Treatment for BPDCN is on Track for EU Approval

According to a story from PR Newswire, the pharmaceutical and diagnostics company The Menarini Group recently announced that its drug tagraxofsup (marketed as Elzonris) has a received a positive opinion…

Continue Reading A New Treatment for BPDCN is on Track for EU Approval

First Patient Treated in NKX101 Trial for AML, MDS

  Recently, biopharmaceutical company Nkarta announced the dosing of the first patient in its Phase 1 clinical trial. Within the trial, researchers will evaluate and analyze the company's investigational therapy,…

Continue Reading First Patient Treated in NKX101 Trial for AML, MDS
Astellas Pharma Provides Help, Guidance, and Hope for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Andrew Krivoshik, M.D., Ph.D., was promoted to senior vice president and Oncology Therapeutic Area Head on April 1, 2019

Astellas Pharma Provides Help, Guidance, and Hope for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Astellas Pharma, headquartered in Northbrook, Illinois presents its Be R/Ready program to promote patient-physician communication as well as other valuable and informative resources. Their program centers around patients with relapsed…

Continue Reading Astellas Pharma Provides Help, Guidance, and Hope for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
This FDA Approved Acute Myeloid Leukemia Drug Got Shut Down in the EU. Why?
source: pixabay.com

This FDA Approved Acute Myeloid Leukemia Drug Got Shut Down in the EU. Why?

According to a story from fiercepharma.com, the US Food and Drug Administration (FDA) was willing to approve the drug Tibsovo as a treatment for acute myeloid leukemia (AML) following encouraging…

Continue Reading This FDA Approved Acute Myeloid Leukemia Drug Got Shut Down in the EU. Why?
A New Investigative Treatment Option for Acute Myeloid Leukemia Produces Positive Results
source: pixabay.com

A New Investigative Treatment Option for Acute Myeloid Leukemia Produces Positive Results

A new study has uncovered that using a hypomethylating agent in combination with a BCL2 inhibitor called Venetoclax may be advantageous as a therapeutic option for individuals with acute myeloid…

Continue Reading A New Investigative Treatment Option for Acute Myeloid Leukemia Produces Positive Results
Experimental Therapies for Small Cell Lung Cancer and Acute Myeloid Leukemia Earn Orphan Drug Designation
source: pixabay.com

Experimental Therapies for Small Cell Lung Cancer and Acute Myeloid Leukemia Earn Orphan Drug Designation

According to a story from BioSpace, the biotechnology company Ascentage Pharma announced that two of its investigational treatments have recently received Orphan Drug designation from the US Food and Drug…

Continue Reading Experimental Therapies for Small Cell Lung Cancer and Acute Myeloid Leukemia Earn Orphan Drug Designation

The First Patient has Been Dosed with an Investigative Therapy for Acute Myeloid Leukemia

Immune-One Therapeutics has just announced that they have dosed their first acute myeloid leukemia (AML) patient in their Phase 1 trial investigating IO-202. This therapy is an immune inhibitory receptor that works…

Continue Reading The First Patient has Been Dosed with an Investigative Therapy for Acute Myeloid Leukemia
2 TP53 Mutations Worsen Blood Cancer Severity, Says Study
source: pixabay.com

2 TP53 Mutations Worsen Blood Cancer Severity, Says Study

Recently, the MDS Foundation announced that two TP53 gene mutations result in worse patient outcomes in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). According to their international and multi center study,…

Continue Reading 2 TP53 Mutations Worsen Blood Cancer Severity, Says Study
Onureg Approved for Continuous AML Treatment
https://pixabay.com/en/skeleton-hand-bones-anatomy-joint-778069/

Onureg Approved for Continuous AML Treatment

Earlier this week, the FDA approved oral azacitidine (Onureg) for patients with acute myeloid leukemia (AML). According to the ASCO Post, Onureg continuously treats adult patients who previously achieved remission.…

Continue Reading Onureg Approved for Continuous AML Treatment
Bemcentinib Meets Efficacy Endpoint for High-Risk MDS and AML
Source: Pixabay

Bemcentinib Meets Efficacy Endpoint for High-Risk MDS and AML

Recently, biopharmaceutical company BerGenBio ASA ("BerGenBio") announced that their drug candidate bemcentinib reached its primary efficacy endpoint in a Phase 2 clinical trial. The drug is designed to treat patients…

Continue Reading Bemcentinib Meets Efficacy Endpoint for High-Risk MDS and AML
Taking It One Step Further in the Quest to Prolong Survival in Acute Myeloid Leukemia
source: pixabay.com

Taking It One Step Further in the Quest to Prolong Survival in Acute Myeloid Leukemia

  Dr. Lindsay Wilde, an oncologist at the Hematologic Malignancies Division of Jefferson University, recently contributed to an article in the Oncology Times outlining her research team’s new study and…

Continue Reading Taking It One Step Further in the Quest to Prolong Survival in Acute Myeloid Leukemia
New Anti-Cancer Drug May Benefit Many Rare Diagnoses
source: pixabay.com

New Anti-Cancer Drug May Benefit Many Rare Diagnoses

A study conducted by researchers from the Institute of Cancer Research in London and Cyclacel has recently been published in PLOS ONE. This investigation examined fadraciclib as a potential therapy…

Continue Reading New Anti-Cancer Drug May Benefit Many Rare Diagnoses
ICYMI: Experimental MDS Combination Shows Promise
source: pixabay.com

ICYMI: Experimental MDS Combination Shows Promise

  According to an article in Globe NewsWire, Onconova Therapeutics, a biopharmaceutical company currently focusing on myelodysplastic syndromes, recently announced results of its Phase 1 study of oral rigosertib in…

Continue Reading ICYMI: Experimental MDS Combination Shows Promise
$6.75 Million in Grants Sets the Stage for the Next Level of Blood Cancer Treatments
source: pixabay.com

$6.75 Million in Grants Sets the Stage for the Next Level of Blood Cancer Treatments

  After forty years of research to counter or cure acute myeloid leukemia and other blood cancers, a few years ago the medical community exploded with eight new cancer drugs.…

Continue Reading $6.75 Million in Grants Sets the Stage for the Next Level of Blood Cancer Treatments
International Panel Gives Expert Advice on the Management of COVID-19 and Blood Cancers
source: pixabay.com

International Panel Gives Expert Advice on the Management of COVID-19 and Blood Cancers

  COVID-19 has now taken hold in over one hundred eighty countries. According to a recent article in The Lancet, in May of 2020, the United States reported the highest…

Continue Reading International Panel Gives Expert Advice on the Management of COVID-19 and Blood Cancers
Dr. Eunice Wang Discusses Newly Approved Treatments for Acute Myeloid Leukemia
source: pixabay.com

Dr. Eunice Wang Discusses Newly Approved Treatments for Acute Myeloid Leukemia

  Earlier this year, The Leukemia & Lymphoma Society hosted a presentation by Dr. Eunice Wang, Clinical Leukemia Service, Professor of Oncology, Roswell Park Comprehensive Cancer Center. Dr. Wang’s presentation…

Continue Reading Dr. Eunice Wang Discusses Newly Approved Treatments for Acute Myeloid Leukemia
New Investigative Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndromes is Being Investigated
source: pixabay.com

New Investigative Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndromes is Being Investigated

Antigen-specific T-cell therapy is an innovative treatment option which uses immune cells to combat cancer cells. AdventHealth is the very first in the world to use this treatment for patients…

Continue Reading New Investigative Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndromes is Being Investigated
Acute Myeloid Leukemia Treatment Granted the Investigational New Drug Designation
source: pixabay.com

Acute Myeloid Leukemia Treatment Granted the Investigational New Drug Designation

Immune-Onc Therapeutics recently received clearance from the FDA to begin trials of IO-202, a treatment for acute myeloid leukemia (AML). This news comes after the cancer immunotherapy company filed an…

Continue Reading Acute Myeloid Leukemia Treatment Granted the Investigational New Drug Designation
Novel Immunotherapy Treatment for AML and MDS Developed by AdventHealth
source: pixabay.com

Novel Immunotherapy Treatment for AML and MDS Developed by AdventHealth

Orlando-based healthcare company AdventHealth developed a novel immunotherapy treatment designed to treat patients with AML and MDS whose conditions failed to respond to other treatments. In addition, the organization is…

Continue Reading Novel Immunotherapy Treatment for AML and MDS Developed by AdventHealth